These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10722507)

  • 21. Indinavir concentrations and antiviral effect.
    Acosta EP; Henry K; Baken L; Page LM; Fletcher CV
    Pharmacotherapy; 1999 Jun; 19(6):708-12. PubMed ID: 10391416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Squires KE; Hammer SM; Fischl MA; Wu H; Cha R; Morse GD;
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1929-35. PubMed ID: 12760869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improvement of onychomycosis without antifungal therapy after initiation of highly active anti-retroviral therapy (HAART) in an HIV-infected patient.
    Tachikawa N; Yasuoka A; Oka S
    Jpn J Infect Dis; 1999 Dec; 52(6):245-6. PubMed ID: 10738363
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
    Descamps D; Flandre P; Joly V; Meiffrédy V; Peytavin G; Izopet J; Tamalet C; Zeng AF; Harel M; Lastère S; Aboulker JP; Yéni P; Brun-Vézinet F;
    J Acquir Immune Defic Syndr; 2002 Dec; 31(5):464-71. PubMed ID: 12473833
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates.
    Rongkavilit C; Thaithumyanon P; Chuenyam T; Damle BD; Limpongsanurak S; Boonrod C; Srigritsanapol A; Hassink EA; Hoetelmans RM; Cooper DA; Lange JM; Ruxrungtham K; Phanuphak P
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3585-90. PubMed ID: 11709344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
    Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
    DiCenzo R; Forrest A; Fischl MA; Collier A; Feinberg J; Ribaudo H; DiFrancecso R; Morse GD;
    Antimicrob Agents Chemother; 2004 Mar; 48(3):918-23. PubMed ID: 14982784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. If taken 1 hour before indinavir (IDV), didanosine does not affect IDV exposure, despite persistent buffering effects.
    Shelton MJ; Mei H; Hewitt RG; Defrancesco R
    Antimicrob Agents Chemother; 2001 Jan; 45(1):298-300. PubMed ID: 11120981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment.
    Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Urien S; Foulongne V; Van De Perre P; Tréluyer JM; Msellati P
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4399-406. PubMed ID: 19581461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.
    Burger DM; van Rossum AM; Hugen PW; Suur MH; Hartwig NG; Geelen SP; Scherpbier HJ; Hoetelmans RM; Vulto AG; de Groot R;
    Antimicrob Agents Chemother; 2001 Mar; 45(3):701-5. PubMed ID: 11181346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.
    Viganò A; Dally L; Bricalli D; Sala N; Pirillo M; Saresella M; Trabattoni D; Vella S; Clerici M; Principi N
    J Pediatr; 1999 Dec; 135(6):675-82. PubMed ID: 10586168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
    AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.
    Pollard RB; Peterson D; Hardy D; Pottage J; Murphy RL; Gathe J; Beall G; Rutkievicz V; Reynolds L; Cross AP; Dunkle LM
    J Acquir Immune Defic Syndr; 1999 Sep; 22(1):39-48. PubMed ID: 10534145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ; Lavelle J; Pollard R; Griffy KG; Wong R; Tarnowski TL; Casserella S; Jung D
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar; 17(3):227-34. PubMed ID: 9495222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
    Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
    AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
    Piscitelli SC; Vogel S; Figg WD; Raje S; Forrest A; Metcalf JA; Baseler M; Falloon J
    Pharmacotherapy; 1998; 18(6):1212-6. PubMed ID: 9855318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.
    Bergshoeff AS; Fraaij PL; van Rossum AM; Verweel G; Wynne LH; Winchell GA; Leavitt RY; Nguyen BY; de Groot R; Burger DM
    Antimicrob Agents Chemother; 2004 May; 48(5):1904-7. PubMed ID: 15105157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.